Janus antimicrobial nanoparticles embedded in polymers
Summary
USPTO published patent application US20260091127A1 for Janus antimicrobial nanoparticles with distinct hydrophobic and polycationic surfaces embedded in crosslinked polymers. The invention aims to enhance traditional antibiotics and reduce necessary dosages against multi-drug resistant bacteria. Application No. 19344327 was filed September 29, 2025, and published April 2, 2026.
What changed
USPTO published a patent application (US20260091127A1) for antimicrobial Janus nanoparticles with distinct hydrophobic and polycationic surfaces encapsulated in crosslinked polymers. The invention claims increased stabilization for long-term effectiveness and enhanced activity against multi-drug resistant bacteria when combined with traditional antibiotics. Inventors include Martijn Zwama, Yan Yu, Swagata Bhattacharyya, and Kunihiko Nishino.
This publication is informational for compliance and legal professionals tracking intellectual property in the antimicrobial/pharmaceutical space. No immediate regulatory action is required. Companies developing antimicrobial coatings, drug delivery systems, or antibiotic adjuvant technologies should monitor this application for potential licensing considerations or freedom-to-operate analysis.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
JANUS PARTICLE-EMBEDDED MATERIALS FOR ANTIMICROBIAL APPLICATIONS
Application US20260091127A1 Kind: A1 Apr 02, 2026
Inventors
Martijn Zwama, Yan Yu, Swagata Bhattacharyya, Kunihiko Nishino
Abstract
Antimicrobial Janus nanoparticles (NPs) having distinct hydrophobic and polycationic surfaces are embedded in crosslinked polymers. These encapsulated Janus NPs have increased stabilization, to allow for long-term effectiveness. The encapsulated Janus NPs enhance traditional antibiotics and reduce the necessary dosage of those traditional antibiotics to inhibit growth of muti-drug resistant bacteria.
CPC Classifications
A61K 47/6929 A61K 38/12 A61P 31/04
Filing Date
2025-09-29
Application No.
19344327
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.